|
|
|
European Biopharmaceutical Review
|
Proteins, proteins, proteins. They are a main feature in our spring edition of EBR –
perhaps not surprisingly, considering the continued increase in
adoption to clinical practice of high-value, high-performing protein
therapeutics and the need for their manufacture at scale by the
biopharmaceutical industry.
Rentschler Biotechnologie’s Dr Stefan R Schmidt and Dr Birgit Schwab
would argue that, considering the market size and recent numbers of US
and European approvals in these drug classes, the future for mid-size
contract development and manufacturing organisations lies in complex
proteins or ‘modern biopharmaceuticals’; monoclonal antibodies and
proteins for cancer and autoimmune conditions in particular (see full
pdf). In their articles, Christian Loch from AVMBioMed (see full pdf)
and Kim Plasman, Kris Gevaert, Francis Impens and Tony Montoye (see full
pdf) agree that, at present, proteomics is the best means for capturing
this vital information.
AVMBioMed highlight the need to consider the importance of
post-translational modification in defining the human protein
repertoire, and the Trinean team plus Kris Gavaert and Francis Impens
flag the need for further improvements in quality to move proteomics
towards a unified regulatory process.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Evonetix Appoints Colin McCracken as Chief Executive Officer
Cambridge, UK, 13 June 2022: EVONETIX LTD (‘Evonetix’), the
synthetic biology company bringing semiconductor technology to DNA
synthesis, today announced the appointment of Colin McCracken as Chief
Executive Officer with immediate effect. Colin’s appointment will
support the next phase of the Company’s development and the
commercialisation of its semiconductor-based DNA synthesis platform.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial-Specific Travel Programs as a Patient Retention Tool
For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >> |
|
|
